IXICO jumps as broker hails ‘pivotal year' and sharp forecast upgrades

IXICO shares jumped 11% to 11.96p after Cavendish called the year “pivotal”, upgraded its price target to 26p (from 24p) and reiterated a buy rating following full-year results showing revenue up 13% to £6.5m, gross profit of £3.2m, an EBITDA loss narrowed to £1.3m (versus an earlier forecasted £1.7m loss) and £3.5m of cash. The broker highlighted progress in diversifying the customer and therapy mix (year-end order book 23% Alzheimer’s, 48% Huntington’s) and faster post-period contract wins that lifted the order book to £17.7m by November (up 27%). Cavendish raised its 2026 revenue forecast by about 8% to £7.5m and gross‑profit estimates by 15%, citing an improving clinical‑trials market and US expansion, and said the stock—trading at under 1x sales—offers meaningful upside as IXICO moves toward sustainable growth and profitability.

Analysis

IXICO shares rose 11% to 11.96p after Cavendish described the year as "pivotal", raised its target to 26p (from 24p) and reiterated a buy rating following full-year results showing revenue up 13% to £6.5m, gross profit of £3.2m, an EBITDA loss narrowed to £1.3m (better than the prior £1.7m forecast) and year-end cash of £3.5m. The broker upgraded 2026 revenue to c.£7.5m (about +8%) and lifted gross-profit estimates by 15%, citing accelerating post-period contract wins that expanded the order book to £17.7m by November (27% above period end). Cavendish highlighted diversification in therapy mix (23% Alzheimer’s, 48% Huntington’s at year-end) and expects continued double-digit growth supported by an improving clinical-trials market and US expansion.

The stock trades below 1x sales, implying a low valuation relative to peers and leaving room for upside if the company sustains the return-to-growth narrative and margin improvement. However, IXICO remains EBITDA-loss making despite improvement and holds modest cash (£3.5m), so near-term financing or sustained order-book conversion will be critical to reach sustainable profitability.

Key catalysts to monitor are sequential contract wins, conversion of the £17.7m order book into revenue, execution in the US and quarterly cash-burn trends; downside risks include slower clinical-trial demand or failure to maintain recent contract momentum.

Key Decisions for Investors

• Consider initiating a small to moderate long position to play the upside from a broker upgrade, upgraded 2026 revenue to ~£7.5m and the sub-1x sales valuation, but size positions for liquidity and execution risk
• Monitor cash runway (year-end £3.5m) and EBITDA trajectory (loss narrowed to £1.3m) and be prepared to increase exposure only if cash burn declines and order-book conversion continues
• Treat November order-book growth to £17.7m and US expansion as primary catalysts; reduce or hedge positions if quarterly updates show slowing contract wins or clinical-trials market weakness
• Use position sizing or protective hedges given remaining loss-making status and small-cap execution risk